Zur Seitenansicht
 

Titelaufnahme

Titel
Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
Verfasser / VerfasserinMandorfer, Mattias ; Scheiner, Bernhard ; Steininger, Lisa ; Semmler, Georg ; Unger, Lukas W. ; Schwabl, Philipp ; Bucsics, Theresa ; Paternostro, Rafael ; Ferlitsch, Arnulf ; Trauner, Michael ; Reiberger, Thomas
Erschienen in
Liver International, 2018, Jg. 39, H. 1, S. 127-135
ErschienenWiley-Blackwell, 2018
SpracheEnglisch
DokumenttypAufsatz in einer Zeitschrift
Schlagwörter (EN)compensated advanced chronic liver disease / controlled attenuation parameter / decompensated cirrhosis / hepatic decompensation
URNurn:nbn:at:at-ubmuw:3-490 Persistent Identifier (URN)
DOI10.1111/liv.13943 
Zugriffsbeschränkung
 Das Werk ist frei verfügbar
Dateien
Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease [0.61 mb]
Links
Nachweis
Klassifikation
Zusammenfassung (Englisch)

Background & Aims

Assessment of hepatic steatosis by transient elastography (TE)based controlled attenuation parameter (CAP) might predict hepatic decompensation. Therefore, we aimed to evaluate the prognostic value of CAP in patients with compensated advanced chronic liver disease (cACLD) and decompensated cirrhosis (DC).

Methods

A total of 430 patients who underwent TE (liver stiffness 10 kPa) and CAP measurements were included in this retrospective analysis. Half of patients (n = 189) underwent simultaneous HVPG measurement. In cACLD patients, first hepatic decompensation was defined by new onset of ascites, hepatic encephalopathy or variceal bleeding. In patients with DC, the following events were considered as further hepatic decompensation: requirement of paracentesis, admission for/development of grade 3/4 hepatic encephalopathy, variceal (re)bleeding or liverrelated death.

Results

First hepatic decompensation occurred in 25 of 292 (9%) cACLD patients, while 46 of 138 (33%) DC patients developed further hepatic decompensation during a median followup of 22 and 12 months respectively. CAP was not predictive of first (cACLD; per 10 dB/m; hazard ratio [HR]: 0.97, 95% confidence interval [95% CI]: 0.911.03, P = 0.321) or further hepatic decompensation (DC; HR: 0.99, 95% CI: 0.941.03, P = 0.554) in adjusted analysis. Using the wellestablished CAP cutoff of 248 dB/m for hepatic steatosis, the incidence of first (cACLD; P = 0.065) and further hepatic decompensation (DC; P = 0.578) was similar in patients with hepatic steatosis or without. Serum albumin levels (per mg/dL; HR: 0.83, 95% CI: 0.770.89, P < 0.001) and MELDNa (per point; HR: 1.15, 95% CI: 1.041.28, P = 0.006) in cACLD and MELDNa (per point; HR: 1.12, 95% CI: 1.051.19, P < 0.0001) in DC patients were the only parameters independently associated with first and further hepatic decompensation, respectively.

Conclusion

Controlled attenuation parameter does not predict the development of first (cACLD)/further (DC) hepatic decompensation, while serum albumin levels and MELDNa are of prognostic value.

Statistik
Das PDF-Dokument wurde 2 mal heruntergeladen.
Lizenz
CC-BY-NC-ND-Lizenz (4.0)Creative Commons Namensnennung - Nicht kommerziell - Keine Bearbeitung 4.0 International Lizenz